Kinetic Insights
Factual, cited reporting on emerging peptide research developments. Published weekly.
Advances in Peptide Stability and Gut Absorption: Overcoming the Oral Bioavailability Challenge
New formulation strategies are improving oral bioavailability of peptide drugs. A look at the absorption enhancer technologies reshaping how researchers approach oral delivery.
12 March 2026GLP-1 Receptor Agonists: Mechanisms Beyond Appetite Suppression
GLP-1 receptor agonists affect more than appetite. Emerging research maps their action on gastric motility, hepatic metabolism, and central reward circuits.
19 March 2026How Obesity Clinical Trial Design Is Evolving Alongside the Drug Pipeline
As obesity drug candidates multiply, trial design must adapt. A look at endpoint selection, comparator arms, and the challenges of long-duration studies.
26 March 2026Peptide Bioconjugation: Linking Molecules to Extend Half-Life and Target Tissues
Bioconjugation strategies — from albumin binding to PEGylation and lipidation — are central to extending peptide half-life. How researchers are engineering next-generation conjugates.
2 April 2026Copper Peptides in Tissue Research: What the Preclinical Data Actually Show
GHK-Cu is widely discussed in the context of tissue repair and skin biology. A review of the preclinical evidence and what remains unvalidated in human studies.
9 April 2026Navigating the FDA Regulatory Pathway for Obesity Peptide Therapeutics
The FDA's evolving framework for obesity drug approval reflects the complexity of a fast-moving field. An overview of regulatory expectations for peptide developers.
16 April 2026Lean Mass Preservation During Pharmacological Weight Loss: An Unresolved Research Question
Weight loss from GLP-1 agonists includes both fat and lean mass. Current research examines the magnitude of lean mass loss and whether adjunct therapies can mitigate it.
23 April 2026Preclinical Obesity Models and Their Translational Limitations
Mouse models of obesity have driven the field for decades, but their translational relevance is limited. How researchers are improving the predictive value of preclinical studies.
30 April 2026Sleep, Peptides, and Appetite: How Circadian Biology Influences Metabolic Research
Sleep restriction alters ghrelin, leptin, and GLP-1 signalling. Understanding circadian peptide dynamics is becoming relevant to metabolic drug development.
7 May 2026Scaling Peptide Manufacturing: CMC Challenges in a Rapidly Expanding Market
Demand for GLP-1 agonists is straining global peptide manufacturing capacity. A look at the chemistry, manufacturing, and controls challenges facing the supply chain.
14 May 2026Oral GLP-1 Agonists: What the Shift from Injectables Means for Research
The first oral GLP-1 receptor agonist for obesity has reached the market. What the shift from injectables means for incretin research.
1 June 2026CVS Caremark Deal Restores Lilly's Obesity Drug Coverage, Reshapes Market Access
CVS Caremark's new formulary agreement with Eli Lilly covers Foundayo and restores Zepbound preferred status, ending Novo Nordisk's exclusive placement.
28 May 2026Kailera's Triple-G Obesity Compound Shows Early-Stage Promise
Phase 1 data from Kailera Therapeutics and Hengrui Medicine suggest their triple agonist may outperform retatrutide in early-stage comparisons.
21 May 2026Retatrutide Meets Endpoints in Pivotal TRIUMPH-1 Trial
Eli Lilly's triple-agonist retatrutide met its primary and key secondary endpoints in the 80-week TRIUMPH-1 obesity trial. What the topline data show.
3 June 2026The Amylin Pathway Steps Forward as a Distinct Research Frontier
Amylin-receptor agonists are emerging as a distinct obesity research frontier. What petrelintide's ZUPREME-1 Phase 2 readout means for the class.
3 June 2026A Five-Receptor Peptide Conjugate Enters the Research Conversation
A research team has linked a GLP-1/GIP peptide to a PPAR ligand, creating a conjugate that activates five receptors. Early preclinical findings explained.
3 June 2026